A Matter-of-fact Way to Health Insurance Coverage for New Health Technologies
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
New health technologies are as the state-of-the-art in the modern medicine and health care that can be applied to various systemic diseases. Regardless of its importance, in many cases the patients are not being able to benefit from new health technologies for their systemic diseases. Hence, they are not covered under health insurance generally, and even covered, it is common that long time is taken to be covered. This study looks at different perspective to the number of previous studies on regenerative medicine as an exemplary case and health insurance coverage, which focused on the clinical results that was beneficial to the patients, researchers and society. In this study, the insured benefits and various non-insured benefits under the health insurance system were examined. Even some regenerative medical services are recognized as safety and efficacy to some degree, the problem of being treated as non-insured medical services due to the new health care technology as itself was discussed through the concept of shadow price. In addition, the study discussed that regenerative medicine proven effectiveness for disease treatments should be included in the insurance benefits, in principle. For this, Japanese cases were referred. The case of Japan may not be fully applicable to all other countries or some specific countries. However, it may be a reference for countries with low protection even though taking public medical insurance systems.
Abstract
New health technologies are as the state-of-the-art in the modern medicine and health care that can be applied to various systemic diseases. Regardless of its importance, in many cases the patients are not being able to benefit from new health technologies for their systemic diseases. Hence, they are not covered under health insurance generally, and even covered, it is common that long time is taken to be covered. This study looks at different perspective to the number of previous studies on regenerative medicine as an exemplary case and health insurance coverage, which focused on the clinical results that was beneficial to the patients, researchers and society. In this study, the insured benefits and various non-insured benefits under the health insurance system were examined. Even some regenerative medical services are recognized as safety and efficacy to some degree, the problem of being treated as non-insured medical services due to the new health care technology as itself was discussed through the concept of shadow price. In addition, the study discussed that regenerative medicine proven effectiveness for disease treatments should be included in the insurance benefits, in principle. For this, Japanese cases were referred. The case of Japan may not be fully applicable to all other countries or some specific countries. However, it may be a reference for countries with low protection even though taking public medical insurance systems.
참고문헌 (17)
- T. Jost, "Health Care Coverage Determinations: An International Comparative Study" (2005), Open University Press
- "Medicare Coverage - Clinical Trials: Final National Coverage Decision"[URL]
- "Ministry of Health, Labor and Welfare"[URL]
- D. Cutler, "The effect of Medicaid expansions on public insurance, private insurance, and redistribution", The American Economic Review, 86, pp.378~383 (1996)
- J. Marton, "Health insurance generosity and conditional coverage: Evidence from medical manage care in Kentucky", Southern Economic Journal, 82, pp.535~555 (2015)[DOI]
- F. Colombo, "Toward more choice in social protection? Individual choice of insurer in basic mandatory health insurance in Switzerland" (2001), OECD
- S. Kwon, "Thirty years of national health insurance in South Korea : lessons for achieving universal health care coverage", Health Policy Plan, 24, pp.63~71 (2009)[DOI]
- National Institute for Health and Care Excellence, "National arrangements for clinical excellence arrangements for topic selection – Overviews of the new system" (2002), NICE
- J. Stiglitz, "Economics" (2002), W. W. Norton & Company Ltd
- M. Lee, "New governmental regulatory system for regenerative medicine in Japan", Tissue Eng Regen Med, 12, pp.167~172 (2015)[DOI]
- K. Kang, "Implications of epigenetics in tissue engineering", Tissue Eng Regen Med, 12, pp.162~166 (2015)[DOI]
- H. Nomura, "The Japanese healthcare system: The issue is to solve the “tragedy of the commons” without making another", BMJ, 331, pp.648~649 (2005)[DOI]
- "Council for Regulatory Reform. Second report regarding promotion of regulatory reform - Priority regulatory reform measures to promote economic vitalization" (2002)[URL]
- Miller S., "Medicaid and Mortality : New Evidence From Linked Survey and Administrative Data", The Quarterly Journal of Economics, 136(3), pp.1783~1829 (2021)[DOI]
- Borgschulte M., "Did the ACA Medicaid expansion save lives?", Journal of Health Economics, 72 (2020)[DOI]
- Petek N., "The marginal benefit of hospitals: Evidence from the effect of entry and exit on utilization and mortality rates", Journal of Health Economics, 86 (2022)[DOI]
- Noghanibehambari H., "Social insurance programs and later-life mortality : Evidence from new deal relief spending", Journal of Health Economics, 86 (2022)[DOI]